More recent findings have demonstrated that nemolizumab, an anti-IL-31RA antibody that binds to IL-31RA with subsequent inhibition of IL-31 signaling effectively relieves AD-associated pruritus (81, 82). The gene discussed is IL31RA; the disease is Pruritus.